Mural Oncology Shareholders Set to Receive $2.035 Cash for Each Share in XOMA Royalty Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Source: NASDAQ.COM
Acquisition Details: Mural Oncology plc will receive a final cash consideration of $2.035 per share from XOMA Royalty Corporation upon closing of their acquisition, as per the Transaction Agreement signed on August 20, 2025.
Regulatory Process: The acquisition will be executed through an Irish High Court-sanctioned scheme of arrangement and is expected to close in early December 2025, pending court approval and satisfaction of remaining conditions.
Company Focus: Mural Oncology is dedicated to advancing immune-oncology therapies, including programs for nemvaleukin alfa, IL-18, and IL-12.
Stock Performance: MURA shares closed at $2.02, down 3.49%, with significant trading volume, and have fluctuated between $0.95 and $4.74 over the past year.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
